Polycystic Kidney Disease | TreatmentTrends | US | 2015

Polycystic kidney disease (PKD) is one of the most common genetic diseases and is characterized by the development and progressive enlargement of fluid-filled cysts in the kidneys. TreatmentTrends® PKD is a syndicated report that provides longitudinal information on market dynamics for the treatment of PKD. This report provides insight into practice patterns, attitudes and perceptions, and projected use of various emerging products. This second report in a series on PKD will primarily focus on autosomal dominant polycystic kidney disease (ADPKD) management in the US.

Questions Answered in This Report:

- One-third (33%) of respondents indicate that the rate of ADPKD diagnosis is increasing (compared with 22% in our 2012 survey). How many patients with ADPKD are nephrologists treating, and what percentages are in each of the chronic kidney disease (CKD) stages? Do nephrologists classify these patients as mild, moderate, or severe? What patient characteristics are considered? What factors do nephrologists believe are associated with disease progression in ADPKD patients? How many ADPKD patients progress to end-stage renal disease (ESRD)?

- ADPKD treatment has remained fairly static with most surveyed nephrologists reporting no changes to their strategies. How is ADPKD diagnosed, and what is the standard of care for patients with PKD? What is the frequency of treatment with pharmacotherapy, cyst decompression surgery, transplant, and/or dialysis? What are the challenges with available treatments and unmet needs in the management of ADPKD? Are physicians satisfied with current pharmacotherapy?

- Unaided awareness of new products in development for ADPKD was low among surveyed nephrologists. What is the interest in products in development for ADPKD, including Tolvaptan (Samsca) by Otsuka, Tesevatinib by Kadmon Pharmaceuticals, and Everolimus by Novartis? What percentage of patients, by stage, are likely candidates for three profiled products in development? What trial end points are most important for agents in development?
Scope:

Markets covered: United States.

Physician research: This report is based on a survey of 100 nephrologists.

Screening criteria: In practice for at least 2 and no more than 30 years and spend more than 75% of their professional time devoted to patient care as opposed to nonclinical activities such as research or teaching. In addition, respondents had to have at least 10 PKD patients under their personal care. Not practicing in Vermont.

Survey fielding dates: The physician surveys were conducted September 2-15, 2015. Surveys were completed over the Internet. Applicable prior wave trending is provided from 2012.

Report: PowerPoint format with 85 pages of content.

Report Details

- Pub Date: November 2015
- Author(s): ["Jihan Khan"]